Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, Nashville, TN, USA; Program in Cancer Biology, Vanderbilt University, Nashville, TN, USA.
Program in Cancer Biology, Vanderbilt University, Nashville, TN, USA.
Free Radic Biol Med. 2018 Nov 1;127:26-35. doi: 10.1016/j.freeradbiomed.2018.05.066. Epub 2018 May 17.
Selenium (Se) is a micronutrient essential to human health, the function of which is mediated in part by incorporation into a class of proteins known as selenoproteins (SePs). As many SePs serve antioxidant functions, Se has long been postulated to protect against inflammation and cancer development in the gut by attenuating oxidative stress. Indeed, numerous studies over the years have correlated Se levels with incidence and severity of intestinal diseases such as inflammatory bowel disease (IBD) and colorectal cancer (CRC). Similar results have been obtained with the Se transport protein, selenoprotein P (SELENOP), which is decreased in the plasma of both IBD and CRC patients. While animal models further suggest that decreases in Se or SELENOP augment colitis and intestinal tumorigenesis, large-scale clinical trials have yet to show a protective effect in patient populations. In this review, we discuss the function of Se and SELENOP in intestinal diseases and how research into these mechanisms may impact patient treatment.
硒（Se）是人体健康所必需的微量元素，其功能部分通过掺入一类称为硒蛋白（SePs）的蛋白质来介导。由于许多 SePs 具有抗氧化功能，因此长期以来人们一直假设硒通过减轻氧化应激来预防肠道炎症和癌症的发展。事实上，多年来的许多研究已经将硒水平与肠道疾病（如炎症性肠病（IBD）和结直肠癌（CRC））的发病率和严重程度相关联。硒转运蛋白硒蛋白 P（SELENOP）也得到了类似的结果，IBD 和 CRC 患者的血浆中 SELENOP 水平降低。虽然动物模型进一步表明硒或 SELENOP 的减少会加剧结肠炎和肠道肿瘤发生，但大规模临床试验尚未显示出对患者人群的保护作用。在这篇综述中，我们讨论了 Se 和 SELENOP 在肠道疾病中的作用，以及对这些机制的研究如何影响患者的治疗。
